Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization

Launched by LIAONING CHENGDA BIOTECHNOLOGY CO., LTD · Apr 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the safety of a Japanese Encephalitis Vaccine (JEV-I) when given to healthy children aged 8 months and older as part of their routine immunizations. The goal is to ensure that the vaccine is safe for these children, as this is an important step in protecting them from the disease. The trial is currently recruiting participants, and it is open to all genders.

To be eligible for this study, children must be healthy and have already received the inactivated Japanese encephalitis vaccine. Parents or guardians must agree to let their child participate by signing a consent form and must be able to attend all scheduled visits for the study. Throughout the trial, participants will be monitored for any side effects or health issues that may arise from the vaccine. This information will help improve our understanding of the vaccine's safety in children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy children who have received the inactivated Japanese encephalitis vaccine.
• • Legal guardian of the participants voluntarily participates in the clinical trial and signs an informed consent form.
• • Legal guardian of the subject has the ability to understand the procedures of the study and accept all scheduled visits.
• Exclusion Criteria:
• • -